Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Raf protein kinases are key components of signal transduction pathways by which specific extracellular stimuli elicit precise cellular responses in mammalian cells.
• Activated cell surface receptors activate ras/rap proteins at the inner aspect of the plasmamembrane which in turn recruit and activate Raf proteins.
• Activated Raf proteins phosphorylate and activate the intracellular protein kinases MEK1 and MEK2.
• activated MEKs catalyse phosphorylation and activation of p42/p44 mitogen-activated protein kinase (MAPK).
• a variety of cytoplasmic and nuclear substrates of activated MAPK are known which directly or indirectly contribute to the cellular response to environmental change.
• Three distinct genes have been identified in mammals that encode Raf proteins; A-Raf, B-Raf and C-Raf (also known as Raf-1) and isoformic variants that result from differential splicing of mRNA are known.
• Inhibitors of Raf kinases have been suggested for use in disruption of tumor cell growth and hence in the treatment of cancers, e.g. histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer and pancreatic and breast carcinoma.
• Raf inhibitors are useful in the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events, including cerebral ischemia after cardiac arrest, stroke and multi-infarct dementia and also after cerebral ischemic events such as those resulting from surgery and/or during childbirth.
• a method of treatment or prophylaxis of a neurotraumatic disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a Raf inhibitor.
• Raf inhibitor in the manufacture of a medicament for the prophylactic or therapeutic treatment of a disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event.
• the Raf inhibitor for use in the invention is preferably a B-Raf inhibitor.
• Neurotraumatic diseases/events as defined herein include both open or penetrating head trauma, such as caused by surgery, or a closed head trauma injury, such as caused by an injury to the head region.
• ischemic stroke particularly to the brain area, transient ischemic attacks following coronary by-pass and cognitive decline following other transient ischemic conditions.
• Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
• the definition Raf inhibitor is also intended to encompass antisense constructs that result in a reduced expression of a Raf kinase within a target cell.
• Small molecule Raf inhibitors include those described in GB2306108,
• Raf inhibitor 4-(4-chloro-3- hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole.
• the use of this compound for the treatment of Raf-mediated cancers is described in Poster 3793, American Association of Cancer Research, New Jersey, April 1998.
• Antisense Raf inhibitors include those described in WO97/10829, US5656612, WO99/02167, US5872232 and WO96/39415.
• Raf inhibitors In order to use Raf inhibitors in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
• Inhibitors may conveniently be administered by any of the routes conventionally used for drug administration, for instance, parenterally, orally, topically or by inhalation. Inhibitors may be administered in conventional dosage forms prepared by combining it with standard pharmaceutical carriers according to conventional procedures. Inhibitors may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
• the pharmaceutical carrier employed may be, for example, either a solid or liquid.
• solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
• liquid carriers are syrup, peanut oil, olive oil, water and the like.
• the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
• time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
• a wide variety of pharmaceutical forms can be employed.
• the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will van'
• the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule or nonaqueous liquid suspension.
• Inhibitors are preferably administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
• the intravenous form of parenteral administration is generally preferred.
• Appropriate dosage forms for such administration may be prepared by conventional techniques.
• Inhibitors may also be administered orally.
• Appropriate dosage forms for such administration may be prepared by conventional techniques.
• Inhibitors may also be administered by inhalation, that is by intranasal and oral inhalation administration.
• Appropriate dosage forms for such administration such as aerosol formulations, may be prepared by conventional techniques.
• Inhibitors may also be administered topically, that is by non-systemic administration. This includes the application of the inhibitors externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
• the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg kg, more preferably from about 0.5 mg to 15mg.
• the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
• the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
• the daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg kg per day.
• the optimal quantity and spacing of individual dosages of the inhibitors will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the inhibitors given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
• the sub-title compound was prepared from 4-chloro-3-methoxybenzoic acid, via its acid chloride, by analogy to the five step procedure (general method B) described by T. F. Gallagher et al, Bioorg. Med. Chem., (1997), 5, 49: MS m/z 362/364 M ⁇ + (electrospray).
• step b) 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole Boron tribromide (5.6 ml, 1M in dichloromethane, 5.6mmol) was added to an ice-cooled solution of the product of step a) (670 mg, 1.85 mmol) in dichloromethane (20 ml). The solution was allowed to warm to ambient temperature and stirred for a further 16h. 5M hydrochloric acid (5 ml) was then added and the mixture heated to reflux for 30 min. After cooling the solution was made alkaline with 40% aqueous sodium hydroxide and the solid product collected by filtration. The residue was washed with ethyl acetate to afford the title compound as a yellow solid: MS m/z 348/350 M ⁇ + (electrospray).
• the activity of compounds as Raf inhibitors may be determined by the following in vitro assay: Raf Kinase assay
• MAP kinase MAP kinase
• Catalytically active human recombinant B-Raf protein was obtained by purification from sf9 insect cells infected with a human B-Raf recombinant baculovirus expression vector. To ensure that all substrate phosphorylation resulted from B-Raf activity, a catalytically inactive form of MEK was utilised.
• This protein was purified from bacterial cells expression mutant inactive MEK as a fusion protein with glutathione-S-transferase (GST- kdMEK).
• GST- kdMEK glutathione-S-transferase
• the neuroprotective properties of Raf inhibitors may be determined by the following in vitro assay: Neuroprotective properties of 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4- pyridyl)-lH-imidazole in rat hippocampal slice cultures
• Organotypic cultures provide an intermediate between dissociated neuronal cell cultures and in-vivo models of oxygen and glucose deprivation (OGD).
• OGD oxygen and glucose deprivation
• the majority of glial-neuronal interactions and neuronal circuitry are maintained in cultured hippocampal slices, so facilitating investigation of the patterns of death among differing cell types in a model that resembles the in vivo situation.
• These cultures allow the study of delayed cellular damage and death 24 hours, or more, post-insult and permit assessment of the consequences of long-term alterations in culture conditions.
• Bound PI shows increased emission at 635nm when excited at 540nm.
• One PI fluorescence image and one white light image are taken and the proportion of cell death analysed.
• the area of region CA1 is defined from the white light image and superimposed over the PI image.
• the PI signal is thresholded and area of PI damage expressed as a percentage of the CA1 area. Correlation between PI fluorescence and histo logically confirmed cell death has been validated previously by Nissl-staining using cresyl fast violet (Newell et al, J Neurosci., (1995b) 15: 7702-7711).
• B-Raf inhibitors are effective inhibitor of the catalytic activity of human B-Raf protein kinase towards its physiologic substrate MAP kinase (MEK). Moreover, B-Raf inhibitors are potent inhibitors of neuronal cell death that results from oxygen glucose deprivation in hippocampal slice cultures. Such neuroprotective properties indicate that B-Raf inhibitors are likely to be of value in prevention of neuronal cell death associated with ischemic stroke and trauma injury.
• MEK MAP kinase

Applications Claiming Priority (5)

Publications (1)

Family

ID=26315478

Family Applications (1)

Country Status (4)

Families Citing this family (9)

Family Cites Families (8)

• 2000
  • 2000-04-26 AU AU45568/00A patent/AU4556800A/en not_active Abandoned
  • 2000-04-26 WO PCT/EP2000/003730 patent/WO2000064422A2/en active Search and Examination
  • 2000-04-26 JP JP2000613413A patent/JP2002542280A/ja active Pending
  • 2000-04-26 EP EP00927054A patent/EP1173254A2/de not_active Withdrawn

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events